Clinical Trial Update: Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. [Phase 3]

View source ↗

Summary

Phase 3 trial update on an anti-IgE monoclonal antibody for allergic asthma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Snippet

Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd. | Conditions: Asthma, Allergic | Phase 3 | Status: COMPLETED